Akero Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

Rhea-AI Summary

Akero Therapeutics (NASDAQ: AKRO), a clinical-stage biotechnology company focused on developing treatments for serious metabolic diseases, has announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference. The company's management will deliver a presentation on Tuesday, June 10, 2025, at 2:40 p.m. ET. Interested parties can access the live webcast through the investor relations section of Akero's website at www.akerotx.com. An archived recording of the presentation will be made available on the company's website following the live event.

SOUTH SAN FRANCISCO, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the Goldman Sachs 46^th Annual Global Healthcare Conference on Tuesday, June 10, 2025, at 2:40 p.m. E.T.

A live webcast of the Company presentation will be available through the investor relations section of the Company's website at www.akerotx.com. Following the live webcast, an archived replay will be available on the Company's website.

About Akero Therapeutics
Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH). Akero’s lead product candidate, efruxifermin (EFX), is currently being evaluated in three ongoing Phase 3 clinical studies: SYNCHRONY Histology in patients with pre-cirrhotic (F2-F3 fibrosis) MASH, SYNCHRONY Outcomes in patients with compensated cirrhosis (F4) due to MASH, and SYNCHRONY Real-World in patients with MASH or MASLD (metabolic dysfunction associated steatotic liver disease). The Phase 3 SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with compensated cirrhosis due to MASH. Akero is headquartered in South San Francisco. Visit us at akerotx.com and follow us on LinkedIn and X for more information.

Investor Contact:
Christina Tartaglia
Precision AQ
332.322.7430
Christina.tartaglia@precisionaq.com

Media Contact:
Peg Rusconi
617.910.6217
peg.rusconi@deerfieldgroup.com

FAQ

When is Akero Therapeutics (AKRO) presenting at the Goldman Sachs Healthcare Conference 2025?

Akero Therapeutics will present at the Goldman Sachs Healthcare Conference on Tuesday, June 10, 2025, at 2:40 p.m. ET.

How can I watch Akero Therapeutics' (AKRO) presentation at the Goldman Sachs conference?

The presentation can be accessed via live webcast through the investor relations section of Akero's website at www.akerotx.com. An archived replay will be available afterward.

What type of company is Akero Therapeutics (AKRO)?

Akero Therapeutics is a clinical-stage company that develops transformational treatments for patients with serious metabolic diseases marked by high unmet medical need.

Will there be a replay available of Akero Therapeutics' (AKRO) Goldman Sachs conference presentation?

Yes, an archived replay of the presentation will be available on Akero Therapeutics' website after the live webcast.